Haemonetics vs PTC Therapeutics

Haemonetics (HAE), health care, and PTC Therapeutics (PTCT), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Haemonetics is worth $5.5B on the stock market and PTC Therapeutics $5B: Haemonetics is valued at 9% more. Haemonetics's operating margin in its latest fiscal year was 11.7% and PTC Therapeutics's 50.1%. Over the past year Haemonetics's share price has moved +63.1% and PTC Therapeutics's -20.5%.

Key facts

Haemonetics market value
$5.5B
PTC Therapeutics market value
$5B
Haemonetics P/E
53.5
Haemonetics revenue
$1.3BFY to 2026-03-28
PTC Therapeutics revenue
$1.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Haemonetics vs PTC Therapeutics: every measure side by side
Measure Haemonetics PTC Therapeutics
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2026-03-282025-12-31
Size
Market cap$5.5Bhigher$5Blower
Revenue$1.3Blower$1.7Bhigher
Earnings$97.3Mlower$682.6Mhigher
Employees3,009higher991lower
Total assets$2.4Blower$2.9Bhigher
Valuation
P/E53.5—
P/S4.1higher2.9lower
P/B6.1—
Dividend yield0.00%0.00%
Profitability
Operating margin11.7%lower50.1%higher
Balance sheet
Net assets$796.3Mhigher-$205.3Mlower
Total liabilities$1.6Blower$3.1Bhigher
Total debt$1.2B—
Cash on hand$245.4Mlower$984.6Mhigher
Price change
Today-0.35%higher-1.00%lower
1 year+63.1%higher-20.5%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Haemonetics only (1)

PTC Therapeutics only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns HAE · Who owns PTCT

Further comparisons

Learn

Questions and answers

Which is bigger, Haemonetics or PTC Therapeutics?

By market value, Haemonetics is the larger: $5.5B against $5B for PTC Therapeutics. By revenue in its latest fiscal year, PTC Therapeutics is the larger: $1.7B against $1.3B for Haemonetics.

Which has the higher operating margin?

PTC Therapeutics: 50.1%, against 11.7% for Haemonetics. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both Haemonetics and PTC Therapeutics?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds Haemonetics and 1 holds PTC Therapeutics.

Cite this page

Funkfolio, “Haemonetics vs PTC Therapeutics”, data as of 18 November 2026. https://funkfolio.com/compare/hae-vs-ptct

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.